10-Tage Monotherapie mit Cabotegravir (GS-6207) bei HIV-Infizierten

Zurück zur Übersicht

21-24.07.2019 / IAS / Mexico City, Mexico

Safety and Antiviral Activity Over 10 Days Following a Single Dose of Subcutaneous GS-6207, a First-in-Class, Long-Acting HIV Capsid Inhibitor in People Living With HIV

by ES Daar, C McDonald, G Crofoot, P Ruane, G Sinclair, H Patel, J Sager, YP Liu, DM Brainard, RH Hyland, MS Rhee

    GS-6207 is a novel, first-in-class, multistage, selective inhibitor of HIV-1 capsid (CA) function GS-6207 can meet significant unmet medical needs for:

    • Antiretrovirals (ARVs) with a novel mechanism of action
    • Heavily treatment-experienced people living with HIV
    • ARVs that require less frequent dosing (ie, long-acting ARVs) In an in vitro study, GS-6207 showed a unique resistance profile that does not overlap with any existing ARVs

    In a previous clinical study in HIV-negative healthy participants, single subcutaneous (SC) doses of GS-6207 up to 450 mg were well tolerated and maintained systemic exposure for over 24 weeks We now report the antiviral activity and safety of SC GS-6207 in people living with HIV

    • Safety data are currently blinded and are reported by cohort

    Studiensammlung zu HIV

    Zur Übersicht